Carlsmed (CARL) vs MiMedx Group (MDXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Carlsmed (CARL) has outperformed MiMedx Group (MDXG) over the past year, gaining 39.5% versus a loss of 54.9%. Carlsmed is the larger company by market cap ($477.4 million vs $445.1 million), about 1.1 times the size. MiMedx Group converts more of its revenue into profit, with a net margin of 11.6% versus -58.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CARL | MDXG |
|---|---|---|
| Share price | $17.42 | $3.05 |
| Market cap | $477.38M | $445.07M |
| 1-day change | +1.16% | -1.93% |
| YTD return | +41.05% | -54.95% |
| 1-year return | +39.47% | -54.88% |
| 5-year return | — | -58.62% |
| Forward P/E | — | 122.00 |
| EPS (TTM) | $-1.13 | $-0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $50.51M | $418.63M |
| Revenue growth (YoY) | +85.94% | +19.99% |
| Net income (latest FY) | $-29.63M | $48.58M |
| Gross margin | 75.31% | 82.56% |
| Operating margin | -60.53% | 15.26% |
| Net margin | -58.67% | 11.60% |
| 52-week high | $19.15 | $7.45 |
| 52-week low | $8.50 | $3.03 |
| Distance from 52-week high | -9.05% | -59.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +26.29% | +129.51% |
| Average volume | 112.80K | 1.39M |
| Shares outstanding | 27.40M | 145.93M |
| Employees | 127 | 808 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CARL has outperformed MDXG by 94.4 percentage points over the past year.
- MiMedx Group is more profitable, keeping 11.6 cents of every revenue dollar as net income versus -58.7 cents for Carlsmed.
- Carlsmed grew revenue faster in its latest fiscal year (+85.94% vs +19.99%).
About Carlsmed
CARL stock →Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures.
Health Care · Medical/Dental Instruments · 127 employees
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Health Care · Medical/Dental Instruments · 808 employees
CARL vs MDXG FAQ
Which is bigger, Carlsmed or MiMedx Group?
Carlsmed (CARL) is larger, with a market capitalization of $477.38M compared with $445.07M for MiMedx Group (MDXG).
Which stock has performed better over the past year, CARL or MDXG?
CARL returned +39.47% over the past 12 months, compared with -54.88% for MDXG (price return, excluding dividends). Past performance does not predict future results.
Are Carlsmed and MiMedx Group in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.